Cytokines and Behcet's Disease

Zhou, Zhenyuan; Chen, S.L.; Shen, Nan; Lu, Yutong

doi:10.1016/j.autrev.2011.12.005

Cited by 130 publications

(92 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the etiopathogenesis of BD remains uncertain, immunological abnormalities including innate and adaptive immunity in humoral and cellular immunity settings are supposed to be the cornerstone of the pathogenesis of BD (13,24). A variety of cytokines such as IL-6, IL-17, IL-18, and IL-21 are increased in BD; moreover, the numerous polymorphisms of the cytokine gene including TNF-α, IL-1, IL-12, IL-23, and IFNγ are also associated with the disease (13,24).…”

Section: Discussionmentioning

confidence: 99%

Low prevalence of obesity in Behçet’s disease is associated with high obestatin level

Koca¹,

Kara²,

Özgen³

et al. 2017

Eur J Rheumatol

View full text Add to dashboard Cite

Objective: Chronic inflammatory diseases are associated with altered body composition. Ghrelin has anti-inflammatory effects, and its level is altered in obesity and inflammatory diseases. The aim of the study was to evaluate the prevalence of obesity and ghrelin and obestatin levels in patients with Behçet's disease (BD). Material and Methods:One hundred and forty-three (143) ). In addition to the routine evaluations (fasting blood glucose, lipid profile, and kidney and liver function tests), serum acylated-ghrelin (AG), unacylated-ghrelin (UAG), total ghrelin (TG) and obestatin levels were analyzed. Student's t-test and chi-square test were used for statistical analysis.Results: The prevalence of obesity was relatively lower in the BD group than in the HC group (12.6% vs. 20.5%, p=0.089). Serum ghrelin levels were similar in the BD and HC groups (p>0.05 for all) although the obestatin level was higher in the BD group compared to the HC group (p<0.001). Serum UAG, TG and obestatin levels were lower in obese BD patients (n=18) than non-obese BD patients (p=0.027, p=0.014 and p=0.001, respectively). Conclusion:The obestatin level was high and the prevalence of obesity was low in the BD group. Moreover, obese BD patients had low obestatin levels. These results suggest that obestatin may protect BD patients from obesity.

show abstract

Section: Discussionmentioning

confidence: 99%

Low prevalence of obesity in Behçet’s disease is associated with high obestatin level

Koca¹,

Kara²,

Özgen³

et al. 2017

Eur J Rheumatol

View full text Add to dashboard Cite

show abstract

“…BD and PFAPA syndrome share different clinical manifestations, and both disorders show a marked cytokine secretion disruption with IL-1β playing a key pathogenetic role [3,4,15,16,18], albeit in different age groups. Triggering infectious factors are supposed to participate in the outbreak of BD in genetically predisposed subjects [19], and even a peculiar dysbiosis of the gut microbiota might be involved in the differentiation of T-regulatory cells of BD patients [20].…”

Section: Discussionmentioning

confidence: 99%

PFAPA syndrome and Behçet’s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists

et al. 2015

View full text Add to dashboard Cite

The pediatric syndrome characterized by periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) and adult Behçet's disease share some clinical manifestations and are both polygenic autoinflammatory disorders with interleukin-1β showing to play a pivotal role. However, the diagnosis is mostly clinical and we hypothesize that specific criteria may be addressed differently by different physicians. To determine the diagnostic variability, we compared the answers of 80 patients with a definite diagnosis of Behçet's disease (age 42.1 ± 13.7 years) obtained by separate telephone interviews conducted by a rheumatologist, a pediatrician, and an internist working largely in the field of autoinflammatory disorders. Questions were related to the age of symptom onset, the occurrence of recurrent fevers during childhood, and the association with oral aphthosis, cervical adenitis and/or pharyngitis, previous treatments, possible growth impairment, the time lapse between PFAPA-like symptoms and the onset of Behçet's disease, and the occurrence of Behçet-related manifestation during childhood. The rheumatologist identified 30 % of patients with Behçet's disease fulfilling PFAPA syndrome diagnostic criteria, compared to the pediatrician and the internist identifying 10 and 7.5 %, respectively. Most of the patients suffered from recurrent oral aphthosis in childhood also without fever (50, 39, and 48 % with each interviewer), yet no patient fulfilled the Behçet's disease diagnostic criteria. Our data suggest that physician awareness and expertise are central to the diagnosis of autoinflammatory disorders through an accurate collection of the medical history.

show abstract

“…Multiple cytokines may contribute to the pathological scenery of BD [10], and interleukin (IL)-1 seems to play a decisive role. Notably, IL-1 has been found to be increased in the serum [11] and synovial fluid [12] of patients with BD, and furthermore the time of disease onset has been correlated with IL-1 gene specific single nucleotide polymorphisms [13,14].…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease

Cantarini

Lopalco

Caso

et al. 2015

Autoimmunity Reviews

View full text Add to dashboard Cite

Cytokines and Behcet's Disease

Cited by 130 publications

References 46 publications

Low prevalence of obesity in Behçet’s disease is associated with high obestatin level

Low prevalence of obesity in Behçet’s disease is associated with high obestatin level

PFAPA syndrome and Behçet’s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists

Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease

Contact Info

Product

Resources

About